PharmaLundensis (PHAL) Q1 2025 earnings summary

Executive summary

• Net sales remained at 0 SEK for the quarter, with a net loss after financial items of -1,447,108 SEK compared to -1,171,737 SEK year-over-year.

• EPS was -0.03 SEK, unchanged from the same quarter last year.

• Soliditet (equity ratio) was 44.6% as of March 31, 2025.

• Successful animal toxicology tests for Phal-501 and development of a pre-evaporation unit expected to boost Minievaporator capacity.

• Rights issue raised approximately 2.53 million SEK.

Financial highlights

• Net sales: 0 SEK (0 SEK year-over-year).

• Net loss after financial items: -1,447,108 SEK (-1,171,737 SEK year-over-year).

• Operating loss: -1,360,770 SEK (-1,084,632 SEK year-over-year).

• Cash and bank: 2,852,299 SEK at period end (1,273,672 SEK at previous year-end).

• Equity at period end: 5,204,655 SEK.

Outlook and guidance

• Existing capital expected to last until year-end, depending on outcome of negotiations with KV1 holders.

• New share issue planned to finance remaining KV1 debt and costs for GMP production of Phal-501 for clinical trials.

• Preparation for first clinical study with Phal-501 underway; GMP production to commence soon.